FFR Versus iFR in Assessment of Hemodynamic Lesion Significance (FiGARO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03033810|
Recruitment Status : Unknown
Verified January 2017 by Tomas Kovarnik, General University Hospital, Prague.
Recruitment status was: Recruiting
First Posted : January 27, 2017
Last Update Posted : January 27, 2017
|Condition or disease||Intervention/treatment|
|Hemodynamics Coronary Circulation Tomography, Optical Coherence Endothelial Cells Polymorphism, Genetic||Device: Fractional flow reserve and instantaneous wave-free ratio|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||FFR Versus iFR in Assessment of Hemodynamic Lesion Significance Using Gene Polymorphisms and Lesion Morphology Assessed by OCT (FiGARO Trial)|
|Study Start Date :||January 2017|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||December 2019|
Consecutive patients with FFR and iFR
Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
Device: Fractional flow reserve and instantaneous wave-free ratio
- Presence of endothelial dysfunction, plaque superficial irregularities and gene polymorphisms in patients with screpancies between FFR and iFR during functional assessments of coronary stenosis. [ Time Frame: 2017-2019 ]Endothelial dysfunction measured by EndoPAT, plaque superficial irregularities measured by OCT and gene polymorphisms in ENOS and HO-1 can be different in patients with discrepancy between FFR and iFR compared to known results from patients with coronary artery disease.
- To use a new software to determine which of two methods for the functional assessment of coronary stenosis (FFR and iFR) perform their measurements during a lower level of microvascular resistance. [ Time Frame: 2017-2019 ]This software will measure microvascular resistance. It´s stable and minimal value is an essential condition for precise assessment of lesion severity by pressure measurement. Lower level of microvascular resistence during FFR or iFR measurements can help to distinguish, which of these two measurements is more relyable.
- To develop a new version of aforementioned software for the detection of microvascular resistance level, based only on intracoronary pressures without flow analysis [ Time Frame: 2017-2019 ]For analysis of microvascular resistance is necessary to measure coronary flow. This type of measurement is time consuming and difficult. The investigators will try to find a marker of low microvascular resistance during assessment of intracoronary pressure, which is easy to measure.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03033810
|Contact: Tomas Kovarnik, MD, PhDemail@example.com|
|Contact: David Zemanek, MD, PhDfirstname.lastname@example.org|